Cargando…

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Zachary A., Frederick, Dennie T., Ahmed, Zain, Wargo, Jennifer A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667913/ https://www.ncbi.nlm.nih.gov/pubmed/23762807 http://dx.doi.org/10.4161/onci.24320

Ejemplares similares

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015)

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
por: Herr, Ricarda, et al.
Publicado: (2015)

BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression
por: Ho, Ping-Chih, et al.
Publicado: (2014)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
por: Sabbatino, Francesco, et al.
Publicado: (2014)

Identification of new prognostic biomarkers for Stage III metastatic melanoma patients
por: Kakavand, Hojabr, et al.
Publicado: (2013)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Fateful music from a talented orchestra with a wicked conductor: Connection between oncogenic BRAF, ER stress, and autophagy in human melanoma
por: Giglio, Paola, et al.
Publicado: (2015)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Re-investigating PLK1 inhibitors as antimitotic agents
por: Delacour, Quentin, et al.
Publicado: (2017)

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014)

Inhibitors of cell cycle checkpoints and DNA replication cause different responses in normal versus malignant urothelial cells
por: Meuth, Mark
Publicado: (2014)

Triple threat treatment: Exploiting the dependence receptor properties of metabotropic glutamate receptor 1 against melanoma
por: Gelb, Tara, et al.
Publicado: (2014)

When unity makes strength: Combinatorial NK cell-based immunotherapies against melanoma
por: Messaoudene, Meriem, et al.
Publicado: (2014)

KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma
por: Murugesan, Navya, et al.
Publicado: (2021)

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma
por: Speeckaert, Reinhart, et al.
Publicado: (2012)

KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance
por: Renner, Philipp, et al.
Publicado: (2014)

Melanoma metastases caught in the AKT
por: Kircher, David A., et al.
Publicado: (2016)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Sustaining the spindle assembly checkpoint to improve cancer therapy
por: Visconti, Roberta, et al.
Publicado: (2015)

The mitosis-differentiation checkpoint, another guardian of the epidermal genome
por: Gandarillas, Alberto, et al.
Publicado: (2015)

Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition
por: McQuade, Jennifer L, et al.
Publicado: (2015)

Melanoma immunoediting by NK cells
por: Balsamo, Mirna, et al.
Publicado: (2012)

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
por: Codarri Deak, Laura, et al.
Publicado: (2023)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade
por: Duraiswamy, Jaikumar, et al.
Publicado: (2013)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

How melanoma cells inactivate NK cells
por: Pietra, Gabriella, et al.
Publicado: (2012)

Disseminating melanoma cells surf on calcium waves
por: Sun, Jianwei, et al.
Publicado: (2015)

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
por: Kim, Hyungsoo, et al.
Publicado: (2015)

Is there a future for adoptive cell transfer in melanoma patients?
por: Besser, Michal J
Publicado: (2013)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Lymphoid neogenesis in melanoma: What does it tell us?
por: van Baren, Nicolas, et al.
Publicado: (2013)

A(2A) blockade enhances anti-metastatic immune responses
por: Beavis, Paul A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1tuhpkev7csc3l4tg3aju2k6lb